JP2018524339A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524339A5
JP2018524339A5 JP2017567655A JP2017567655A JP2018524339A5 JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5 JP 2017567655 A JP2017567655 A JP 2017567655A JP 2017567655 A JP2017567655 A JP 2017567655A JP 2018524339 A5 JP2018524339 A5 JP 2018524339A5
Authority
JP
Japan
Prior art keywords
ring
alkyl
compound
optionally
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017567655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524339A (ja
JP7099824B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/065499 external-priority patent/WO2017001660A1/en
Publication of JP2018524339A publication Critical patent/JP2018524339A/ja
Publication of JP2018524339A5 publication Critical patent/JP2018524339A5/ja
Priority to JP2021194493A priority Critical patent/JP7516338B2/ja
Application granted granted Critical
Publication of JP7099824B2 publication Critical patent/JP7099824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017567655A 2015-07-02 2016-07-01 抗菌化合物 Active JP7099824B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021194493A JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15174936 2015-07-02
EP15174936.3 2015-07-02
EP16174718 2016-06-16
EP16174713 2016-06-16
EP16174718.3 2016-06-16
EP16174713.4 2016-06-16
PCT/EP2016/065499 WO2017001660A1 (en) 2015-07-02 2016-07-01 Antibacterial compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194493A Division JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Publications (3)

Publication Number Publication Date
JP2018524339A JP2018524339A (ja) 2018-08-30
JP2018524339A5 true JP2018524339A5 (cg-RX-API-DMAC7.html) 2019-08-08
JP7099824B2 JP7099824B2 (ja) 2022-07-12

Family

ID=56289523

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017567289A Pending JP2018519302A (ja) 2015-07-02 2016-07-01 抗菌化合物
JP2017567655A Active JP7099824B2 (ja) 2015-07-02 2016-07-01 抗菌化合物
JP2021194493A Active JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017567289A Pending JP2018519302A (ja) 2015-07-02 2016-07-01 抗菌化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021194493A Active JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Country Status (29)

Country Link
US (6) US10364232B2 (cg-RX-API-DMAC7.html)
EP (3) EP4074378A1 (cg-RX-API-DMAC7.html)
JP (3) JP2018519302A (cg-RX-API-DMAC7.html)
KR (2) KR20180022833A (cg-RX-API-DMAC7.html)
CN (3) CN108235704B (cg-RX-API-DMAC7.html)
AU (3) AU2016287477B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017028318B1 (cg-RX-API-DMAC7.html)
CA (1) CA2986331A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017003404A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017013408A2 (cg-RX-API-DMAC7.html)
DK (1) DK3316969T3 (cg-RX-API-DMAC7.html)
EA (2) EA201890204A1 (cg-RX-API-DMAC7.html)
ES (1) ES2914681T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249468A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20220339T1 (cg-RX-API-DMAC7.html)
IL (2) IL256391B (cg-RX-API-DMAC7.html)
LT (1) LT3316969T (cg-RX-API-DMAC7.html)
MA (1) MA42293A (cg-RX-API-DMAC7.html)
MD (1) MD3316969T2 (cg-RX-API-DMAC7.html)
MX (2) MX2017016789A (cg-RX-API-DMAC7.html)
PE (1) PE20180520A1 (cg-RX-API-DMAC7.html)
PH (2) PH12017502298B1 (cg-RX-API-DMAC7.html)
PL (1) PL3316969T3 (cg-RX-API-DMAC7.html)
RS (1) RS63201B1 (cg-RX-API-DMAC7.html)
SI (1) SI3316969T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200220T1 (cg-RX-API-DMAC7.html)
UA (1) UA125171C2 (cg-RX-API-DMAC7.html)
WO (2) WO2017001661A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708692B (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958966C (en) 2014-08-28 2020-01-14 Asceneuron Sa Substituted cyclic amines as glucosidase inhibitors
CN108235704B (zh) 2015-07-02 2021-10-26 爱尔兰詹森科学公司 抗细菌化合物
CA2988601C (en) 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
PE20181352A1 (es) 2015-09-17 2018-08-22 Marvin J Miller Compuestos heterociclicos que contienen bencilamina y composiciones utiles contra infeccion por micobacterias
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
CA3012624A1 (en) 2016-02-25 2017-08-31 Asceneuron S.A. Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
SI3429591T1 (sl) 2016-03-16 2023-07-31 Kura Oncology, Inc. Substituirani tieno(2,3-d)pirimidinski derivati kot inhibitorji menin-MLL in postopki uporabe
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP3526219B1 (en) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
AU2018216040A1 (en) 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy
EP3672959A1 (en) 2017-08-24 2020-07-01 Asceneuron SA Linear glycosidase inhibitors
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
WO2019079410A1 (en) 2017-10-17 2019-04-25 Vanderbilt University ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
RU2680972C1 (ru) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков
US20210009583A1 (en) * 2018-03-12 2021-01-14 University Of Notre Dame Du Lac Deuterated imidazopyridines
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
MX2021002111A (es) 2018-08-22 2021-07-16 Asceneuron S A Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa.
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
CN109503631A (zh) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用
WO2020243224A1 (en) * 2019-05-28 2020-12-03 Shionogi & Co., Ltd. A MEDICAMENT FOR TREATING MYCOBACTERIAL INFECTION CHARACTERIZED BY COMBINING A CYTOCHROME bc1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
KR102076958B1 (ko) 2019-06-24 2020-02-13 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
ES2978573T3 (es) 2019-09-13 2024-09-16 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos
CA3149988A1 (en) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont 4-QUINOLINONE ANTIBACTERIAL COMPOUNDS
MX2022003816A (es) 2019-09-30 2022-05-06 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
KR20220122649A (ko) 2019-12-27 2022-09-02 테크니메데 소시에다데 테크니코-메디시날 에스.에이. 신규한 약학 조성물(new pharmaceutical compounds)
WO2022194803A1 (en) 2021-03-16 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022194906A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
CA3223626A1 (en) 2021-06-29 2023-01-05 Augusto Eugenio Pardal Filipe Heterocyclic compounds for the treatment of tuberculosis
KR20240090864A (ko) 2021-10-28 2024-06-21 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 세균성 감염의 치료에 사용하기 위한 이미다조피리딘 아미드 및 관련 화합물
CN114957954B (zh) * 2022-05-16 2024-08-20 万华化学集团股份有限公司 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用
JP2025520414A (ja) * 2022-06-15 2025-07-03 シーフォー セラピューティクス, インコーポレイテッド Smarca2を標的化分解する化合物
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
WO2025017047A1 (en) 2023-07-18 2025-01-23 Janssen Pharmaceutica Nv Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2193201T3 (es) 1994-11-15 2003-11-01 Upjohn Co Agentes antibacterianos tipo oxazolidonas sustituidas con oxazina y tiazina biciclica.
CN1068328C (zh) 1995-05-11 2001-07-11 法玛西雅厄普约翰美国公司 螺环和双环二嗪基和咔嗪基噁唑烷酮类
JP4484703B2 (ja) 2002-07-25 2010-06-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キノリン誘導体およびミコバクテリア抑制剤としてのそれらの使用
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
CL2008001631A1 (es) * 2007-06-06 2009-01-02 Smithkline Beecham Corp Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
CA2712613C (en) 2008-03-26 2017-02-28 Global Alliance For Tb Drug Development Bicyclic nitroimidazoles covalently linked to substituted phenyl oxazolidinones
CN102187224A (zh) 2008-09-22 2011-09-14 俄勒冈健康科学大学 用于检测结核分枝杆菌感染的方法
CA2748274A1 (en) 2008-12-30 2010-07-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors
EP3257854A1 (en) 2009-11-05 2017-12-20 University of Notre Dame du Lac Imidazo[1,2-a]pyridine compounds, synthesis thereof, and methods of using same
CA2793086C (en) * 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
JP2014525447A (ja) 2011-09-01 2014-09-29 アイアールエム・リミテッド・ライアビリティ・カンパニー c−Kitキナーゼ阻害剤としての化合物および組成物
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
UY34301A (es) 2011-09-01 2013-04-05 Irm Llc COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit
HUE032035T2 (en) * 2012-03-02 2017-08-28 Genentech Inc Amido spirocyclic amide and sulfonamide derivatives
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN104718213B (zh) * 2012-07-18 2018-02-27 圣母大学 5,5‑杂芳族抗感染化合物
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
US20160185774A1 (en) * 2013-08-02 2016-06-30 Institut Pasteur Korea Anti-Infective Compounds
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
JP2017533220A (ja) 2014-11-03 2017-11-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 結核処置のための多剤療法
CN108235704B (zh) * 2015-07-02 2021-10-26 爱尔兰詹森科学公司 抗细菌化合物
BR112018075939A2 (pt) 2016-06-16 2019-04-09 Janssen Sciences Ireland Unlimited Company compostos heterocíclicos como antibacterianos
MA45377A (fr) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Co Composés hétérocycliques en tant qu'agents antibacteriens
EP4417262A3 (en) 2017-03-01 2024-11-27 Janssen Sciences Ireland Unlimited Company Combination therapy

Similar Documents

Publication Publication Date Title
JP2018524339A5 (cg-RX-API-DMAC7.html)
JP2018519302A5 (cg-RX-API-DMAC7.html)
JP2019518046A5 (cg-RX-API-DMAC7.html)
JP2019518050A5 (cg-RX-API-DMAC7.html)
JP2018536648A5 (cg-RX-API-DMAC7.html)
JP2008195730A5 (cg-RX-API-DMAC7.html)
JP2019094345A5 (cg-RX-API-DMAC7.html)
JP2012524053A5 (cg-RX-API-DMAC7.html)
JP2020510010A5 (cg-RX-API-DMAC7.html)
JP2006507265A5 (cg-RX-API-DMAC7.html)
CN111836814A (zh) 稠环化合物、其制备方法及用途
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2005502621A5 (cg-RX-API-DMAC7.html)
JP2004517099A5 (cg-RX-API-DMAC7.html)
JP2008201787A5 (cg-RX-API-DMAC7.html)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
JP2013542267A5 (cg-RX-API-DMAC7.html)
JP2014505017A5 (cg-RX-API-DMAC7.html)
JP2019519616A5 (cg-RX-API-DMAC7.html)
JP2019520344A5 (cg-RX-API-DMAC7.html)
JP2024539645A (ja) インテグリン阻害剤及び他の薬剤と組み合わせたその使用
JPWO2021030556A5 (cg-RX-API-DMAC7.html)
EP2124930B1 (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
JP2015522592A5 (cg-RX-API-DMAC7.html)
ITMI980442A1 (it) Sali nitrati di farmaci antiulcera